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Management of Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) is an important public health problem and is associated 
with considerable morbidity and mortality. Therefore, treatment of this condition is of 
paramount importance. The treatment of OSA includes general and behavioural 
measures, mechanical measures including continuous positive airway pressure 
(CPAP), Bilevel positive airway pressure (BiPAP) and Oral Appliances (OA), 
pharmacological treatment and surgical procedures. Continuous positive airway 
pressure (CPAP) treatment reverses the repetitive upper airway obstruction of sleep 
apnea and associated daytime sleepiness and is the most effective treatment for OSA. 
However maintaining patient adherence to CPAP therapy is a challenge. Weight loss 
should be recommended to overweight patients with OSA, as it has been shown that 
weight reduction has additional health beneﬁts. Treatment of underlying medical 
conditions such as hypothyroidism or acromegaly has profound effect on 
apnea/hypopnea index. A subset of patients with OSA may beneﬁt from supplemental 
oxygen and positional therapy. Presently, there are no effective pharmacotherapeutic 
agents for treatment of patients with OSA and the role of surgical treatment in OSA is 
controversial. However, pharmacological treatment of persisting residual sleepiness, 
despite adequate positive airway pressure therapy delivery and adherence, is indicated 
and may improve daytime sleepiness.
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INTRODUCTION
There are several consequences 
that are associated with obstructive sleep 
apnea (OSA) (1). Life threatening 
cardiovascular complications can occur in 
patients with OSA. The treatment of OSA 
is of utmost importance not only to 
prevent serious consequences, but also to 
improve the quality of life of such 
individuals. The treatment of OSA 
includes general and behavioural 
measures, mechanical measures including 
continuous positive airway pressure 
(CPAP), Bilevel positive airway pressure 
(BiPAP) and Oral Appliances (OA), 
pharmacological treatment and surgical 
procedures.
General and behavioural measures :
General measures include weight 
reduction, avoidance of alcohol at least 4 
to 6 hours prior to bed time, avoidance of 
sedative drugs that are known to make 
apnea worse, smoking cessation, sleeping 
on one's side rather than on the back or 
stomach and avoiding sleep deprivation. 
As obesity is an important factor in the 
causation of OSA, it has been observed 
that a 10% reduction in weight was 
associated with clinically signiﬁcant 
improvement in apnea-hypopnea index 
(2, 3). There are several beneﬁts from 
reduction of weight in OSA and these 
i n c l u d e  d e c r e a s e  i n  r e s p i r a t o r y 
disturbance index (RDI), lowering of 
blood pressure, improvement in sleep 
structure and snoring and improvement in 
pulmonary function and arterial blood gas 
values. There is also a possibility that 
weight reduction may reduce the optimum 
CPAP pressure required. Longitudinal 
studies are required to assess the long-
term effects of methods of weight loss 
(e.g. bariatric surgery and carbohydrate-
restricted diets) on the severity of OSA   
(4, 5).  
Mechanical measures :
Mechanical measures include 
positive airway pressure with a CPAP or 
bilevel positive airway pressure (BiPAP) 
and oral appliances (OA). The standard 
treatment of OSA is with CPAP. The 
treatment of OSA should start from least 
invasive and effective to most invasive 
and effective. All patients with OSA 
should be offered nasal CPAP ﬁrst. 
Patients with mild-to-severe OSA who 
refuse or reject CPAP therapy may be 
offered the next choice, i.e. BiPAP 
therapy. If BiPAP therapy also fails, OA 
therapy may be considered (5). Oral 
appliances can be the ﬁrst line therapy in 
mild OSA, if they are unwilling to use 
CPAP. 
a) CPAP therapy :
CPAP therapy is the ﬁrst-line 
standard of care for treating OSA and this 
is the only intervention shown to have a 
favourable impact on both cardiovascular 
and neurobehavioral morbidities. A 
“pneumatic spl int” is  created by 
delivering a fan-generated ﬂow and thus 
CPAP maintains airway patency. CPAP 
dramatically reduces or eliminates apnea 
and hypopnea in most patients (6). The 
effectiveness of CPAP depends on the 
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utilization of the machine and mask by the 
patients. Approximately, 25-50% of 
patients either will refuse CPAP therapy or 
cannot tolerate it. Of the patients who 
accept CPAP, about 40-60% of them 
continue to use it for one year or longer. 
Nonadherence to the use of CPAP is 
therefore a major therapeutic challenge. 
When adherence is deﬁned as greater than 
4 hours of nightly use, 46 to 83% of 
patients with obstructive sleep apnea have 
been reported to be nonadherent to 
treatment. Evidence suggests that use of 
CPAP for longer than 6 hours decreases 
sleepiness, improves daily functioning, 
and restores memory to normal levels. No 
single factor has been consistently 
identiﬁed as predictive of adherence. 
Emerging data suggest that various 
behavioural interventions may be 
effective in improving CPAP adherence 
(7, 8).
Patients who have been diagnosed 
as having OSA and who require CPAP 
treatment, have titration of pressure over 
an entire night (full-night polysomnogram 
(PSG) titration) during a technician-
attended PSG. Titration is usually done by 
a trial and-error process and the technician 
adjusts the applied pressure until 
respiratory and sleep parameters that are 
considered to be clinically important are 
reduced to the degree judged by the 
clinician to be acceptable (9). The 
pressure needed typically is 5-20 cm H O. 
2
Auto adjusting CPAP (A-CPAP) devices 
are  in tended to  detect  breathing 
d is turbances  or  absence  of  such 
disturbances over speciﬁed intervals and 
modify the applied positive airway 
p r e s s u r e  u p w a r d  o r  d o w n w a r d , 
respectively, in real time, according to a 
device-speciﬁc algorithm. Split-night 
PSG titration is an attended, in-laboratory, 
overnight procedure during which sleep 
and breathing variables are recorded for 
diagnostic purposes during the ﬁrst  hours 
of the sleep period, after which, if speciﬁc 
criteria are met, CPAP titration is 
performed during the remainder of the 
night. Split-night PSG titration may 
provide a pressure prescription that is 
comparable to that of full-night PSG 
titration in patients who demonstrate 
frequent obstructive events early in the 
sleep period (6).  Patients with moderate 
to severe sleep disordered breathing 
(apnea-hypopnea index greater than 15) 
should be treated with CPAP irrespective 
of their symptoms because these patients 
are at increased risk of cardiovascular 
morbidity. Patients with mild form of 
OSA (AHI 5 to 14.9) can be treated with 
CPAP if they have one of the following i.e. 
e x c e s s i v e  d a y t i m e  s l e e p i n e s s , 
hypertension or coexistent cardiovascular 
disease. Conventional CPAP therapy 
applies ﬁxed pressure continuously to the 
patient. Since respiration is a dynamic 
process applying a ﬁxed pressure 
continuously may not be appropriate. 
Therefore, CPAP devices are currently 
available that automatically change 
pressures based on the presence and/or 
absence of OSA (auto-positive airway 
pressure, auto-PAP). CPAP has been 
reported to improve daytime sleepiness, 
cognitive function and quality of life and 
also has been found to decrease blood 
pressure and health care costs (6).  
Important drawback of CPAP therapy is 
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the poor adherence to CPAP therapy. 
Many patients do not accept CPAP 
devices and many do not regularly report 
for follow up visits (8). Complications of 
CPAP therapy include a sensation           
of  suffocation or claustrophobia, 
musculoskeletal discomfort, aerophagia 
a n d  s i n u s  d i s c o m f o r t .  R a r e l y 
pneumothorax, pneumomediastinum and 
tympanic membrane rupture have been 
reported.
b) BiPAP Therapy :
Whereas CPAP delivers a constant 
pressure during both inspiration and 
expiration, BiPAP allows independent 
adjustment of the pressures delivered 
during inspiration and expiration. BiPAP 
therapy is prescribed in patients with OSA 
who cannot tolerate high CPAP pressure 
or have complications following CPAP 
therapy i.e. ear infections, bloating etc. 
(5). There is no distinct advantage of 
BiPAP over CPAP therapy.
c) Oral appliances :
The indications for oral appliances 
are OSA patients with mild-to-moderate 
OSA who prefer OA to CPAP therapy, 
who do not respond to CPAP therapy and 
in whom the CPAP therapy had failed. 
Therefore OA is not indicated in patients 
with severe OSA (5). There are three basic 
designs of OAs. These are mandibular 
repositioners, tongue retaining devices 
and palatal lifting devices. There are more 
than 40 OAs available to manage sleep 
r e l a t ed  b r ea th ing  d i so rde r s  and 
o b s t r u c t i v e  s l e e p  a p n e a . 
Contraindications to the use of OAs are 
less number of teeth, patient is unable to 
protrude the mandible forward and open 
jaw widely, pre-existing tempero-
mandibular joint problems, severe 
bruxism and patients with full dentures. 
Complications of oral appliances include 
excessive salivation, dental misalignment 
with bite change, tempero-mandibular 
joint disease, gum irritation, salivation 
and tongue pain (5).
Pharmacologic treatment :
a) Serotonergic agents :
It has been observed that serotonin 
contributes to upper airway patency and 
that serotonergic agent reduces sleep-
related breathing events both in rapid eye-
movement (REM) and non-REM sleep in 
an animal model of OSA. Selective 
serotonin reuptake inhibitors (ﬂuoxetine 
and paroxetine) have been shown to 
decrease apnea-hypopnea index (10). 
Mitrazapine is a piperazinoazepine-
derivative tetracyclic antidepressant and 
is also a 5-HT antagonist. It is thought to 
act as a central ventilatory stimulant as it 
has  effects  a t  noradrenergic  and 
histaminergic receptors. Though it has 
been shown to reduce AHI by almost 50%, 
i t s  a n t i h i s a m i n e rg i c  p r o p e r t i e s 
compromises its utility in OSA. It causes 
weight gain in many subjects. However 
these selective serotonin reuptake 
inhibitors are not currently recommended 
for treating OSA.
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b) REM suppressants :
As atonia is a feature of rapid eye 
movement (REM) sleep interfering with 
t h o r a c o - a b d o m i n a l  m u s c l e s  o f 
respiration, REM suppressants have been 
suggested as therapeutic agents for 
treatment of OSA. A subset of patients 
develops OSA and hypopnea events 
almost exclusively during REM sleep. 
These patients may be candidates for 
REM suppressant therapy.  It has been 
observed that many drugs including 
ﬂuoxe t ine ,  pa roxe t ine ,  t r i cyc l i c 
antidepressants, alcohol and stimulants 
( d e x o a m p h e t a m i n e )  h a v e  R E M -
suppressing effects. Two other REM 
suppressants evaluated for treatment of 
OSA are protryptiline and clonidine. 
Protryptiline is a tricyclic antidepressant 
having anticholinergic, serotonin and 
noradrenergic reuptake inhibitory effects. 
P ro t ryp t i l ine  has  been  found  to 
signiﬁcantly reduce apnea/hypopnea 
index (AHI), however there was no 
r educ t ion  in  REM AHI .  Though 
protryptiline may reduce AHI, the 
reduction is not sufﬁcient to recommend 
i t s  u s e  i n  O S A .  C l o n i d i n e  i s  a 
noradrenergic alpha  agonist and is used 
2
as an antihypertensive drug. Clonidine 
was evaluated for the treatment of OSA 
because of its REM suppressant effect. 
However, clonidine is not recommended 
for treatment of OSA as it has major side 
effects such as CNS depression and 
orthostatic hypotension (11, 12). The 
effectiveness of REM suppressants in the 
treatment of OSA is not determined (10).
c) Ventilatory stimulants :
M e t h y l  x a n t h i n e s ,  o p i o i d 
antagonist (naloxone), doxopram and 
nicotine are the drugs evaluated as 
ventilatory stimulants for treatment of 
OSA.  Nicotine is used as a smoking 
cessation drug and it has both CNS and 
respiratory stimulant effects. However 
none of these drugs are having promising 
effects to be recommend for OSA 
treatment (13, 14).
d) Wake promoting substances (e.g. 
Modaﬁnil and armodaﬁnil) :
Despite treatment with CPAP, 
many patients demonstrate residual 
sleepiness. Wake promoting substances 
are advocated as an adjunctive treatment 
for such residual sleepiness. Modaﬁnil is a 
wake-promoting agent which has been 
approved for the treatment of narcolepsy. 
Modaﬁnil was therefore evaluated in 
pa t ien ts  wi th  excess ive  dayt ime 
sleepiness and this drug has no effect on 
AHI. In a randomized, double blind, 
placebo-controlled parallel group trial, 
modaﬁnil was evaluated in a group of 
patients who were treated with CPAP and 
with residual sleepiness (dose 200 mg/day 
week 1 and then 400 mg/day weeks 2-4). It 
was observed that modaﬁnil signiﬁcantly 
improved daytime sleepiness (15). The 
common adverse events are headache, 
nausea and infection. It has been reported 
that life-threatening skin reactions may 
occur with modaﬁnil. Other adverse 
events reported are psychiatric symptoms. 
Modaﬁnil may be given to adult patients 
with OSA having excessive somnolence 
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despite well treated with CPAP (10).
e) Hormonal treatment :
T h e r e  a r e  n o  r a n d o m i z e d 
prospective studies that have evaluated 
h o r m o n a l  r e p l a c e m e n t  ( e . g . 
Medroxyprogesterone and oestrogen) 
treatment on prevention of OSA. It has 
been hypothesized that increased 
incidence of OSA in postmenopausal 
women is due the loss of protective effect 
of estrogen and progesterone. Several 
studies evaluated the role of these 
hormones in the treatment of OSA. 
However, there are no consistent data to 
show the beneﬁcial effects from hormone 
replacement treatment in OSA (16).
f)  Endocrinological disorders :
i) Thyroid hormone replacement 
therapy : 
Hypothyroidism is an important 
risk factor for development of OSA. All 
patients with OSA require evaluation to 
exclude hypothyroidism. . Thyroid 
hormone replacement therapy completely 
reverses OSA due to hypothyroidism. 
Reversal of OSA in such situation may 
take one year (17).
ii) Growth hormone suppressant 
therapy in acromegaly :
   Patients with OSA may require 
evaluation for acromegaly as it is 
associated with OSA. If acromegaly is 
suspected ,  such  pa t ien ts  requi re 
appropriate endocrine evaluation. 
Bromocr ip t ine  and oct reot ide  (a 
somatostatin analog) have been found to 
signiﬁcantly reduce AHI in patients with 
acromegaly (18, 19).
g) Supplemental Oxygen :
Intermittent hypoxia has been 
implicated as the underlying mechanism 
for the systemic manifestations seen in 
OSA. Supplemental nocturnal oxygen 
therapy was evaluated in patients with 
OSA. It was observed that oxygen 
administration improved nocturnal 
oxygen saturation levels but does not 
improve airway patency (20).
h) Improvement of nasal patency :
Patients with OSA and coexisting 
rhinitis may beneﬁt from the use of nasal 
corticosteroids. However this alone will 
not be sufﬁcient to treat OSA (21).
I) Positional therapies :
Lateral positioning therapy has 
been found to improve AHI (22). Use of 
specially designed pillows to improve 
neck and body position in sleep requires 
further evaluation (23).
j) Antioxidants :
An imbalance in the oxidant-anti-
oxidant status has been implicated in the 
d e v e l o p m e n t  o f  c a r d i o v a s c u l a r 
abnormalities in patients with OSA. There 
is not only an increase in pro-oxidants but 
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also a decrease in anti-oxidants. It is 
recognised that when there is oxidative 
stress, there is an increase in the 
production of the inﬂammatory cytokines 
which in turn would produce further free 
radicals, thus forming a vicious cycle and 
worsening the disease condition. Oral N-
acetylcysteine (NAC), an antioxidant, 
administrat ion appears to have a 
therapeutic potential in the treatment of 
OSA (24). Compared to a previous 
investigation in which the anti-oxidants 
used were vitamins E and C, there was a 
greater  increase in total  reduced 
glutathione (GSH) level in the NAC group 
(24, 25).
Surgical Treatment :
The role  of  surgery in  the 
treatment of OSA is controversial. 
Patients with reversible upper airway 
obstruction such as adenotonsillar 
hyper t rophy or  mass  les ions  are 
candidates for surgery with beneﬁcial 
effects. Uvulopalatopharyngoplasty is a 
commonly performed surgery in OSA in 
which soft palatal tissue is excised, but 
with suboptimal results (26). Mandibular 
advancement devices have been found to 
be effective in mild apnea and may 
improve daytime symptoms (27). Other 
surgical procedures attempted for 
treatment of OSA are septoplasty, nasal 
polypectomy, radiofrequency ablation of 
turbinates, uvulopalatal ﬂap, palatal 
advancement, radiofrequency ablation of 
the soft palate, genioglossal advancement, 
hyoid suspension, partial glossectomy, 
tongue  rad io f requency  ab la t ion , 
l ingualplasty, maxillo-mandibular 
advancement and epiglottoplasty. It has 
also been reported that bariatric surgery 
may be useful. However, there are no 
randomised trials showing the efﬁcacy of 
bariatric surgery in OSA. Tracheostomy, 
though very effective in the treatment of 
OSA, is a disﬁguring procedure and 
decreases the quality of life of the patients. 
Tracheostomy is therefore reserved for 
patients with severe OSA in whom other 
medical and surgical procedures have 
failed (5).
Hypoglossal Nerve Stimulation :
S i n c e  h y p o g l o s s a l  n e r v e 
stimulation (HGNS) recruits lingual 
muscles  and reduces  pharyngeal 
col lapsibi l i ty,  i t  i s  possible  that 
stimulation of hypoglossal nerve may be 
used to treat sleep apnea.  A Hypoglossal 
Nerve Stimulation System (HGNS) was 
implanted in patients with OSA to test this 
hypothesis.  It has been shown that 
hypoglossal nerve stimulation produced 
marked dose-related increases in airﬂow 
without arousing patients from sleep, 
suggesting that hypoglossal nerve 
s t imula t ion  i s  a  po ten t ia l  nove l 
therapeutic approach for patients with 
OSA (28). 
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